Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | USP1 | O94782 | 3/20 | 0.40 |
| ▸ | USP8 | P40818 | 3/20 | 0.40 |
| ▸ | OTUB1 | Q96FW1 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 5/20 | 0.39 |
| ▸ | HTR2B | P41595 | 4/20 | 0.39 |
| ▸ | USP36 | Q9P275 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5242990 | 0.83 | CHEK2 (0.47) | NOS3NOS1NOS2HTR2CUSP30 | |
| SCHEMBL4696842 | 0.83 | CHEK2 (0.47) | NOS3NOS1NOS2HTR2CUSP30 | |
| SCHEMBL4698797 | 0.81 | HTR2A (0.41) | HTR2CUSP30HTR2AGAASMN1; SMN2 | |
| SCHEMBL1166961 | 0.78 | NOS3 (0.42) | NOS3NOS1NOS2HTR2CHTR2B | |
| SCHEMBL1166959 | 0.78 | NOS3 (0.42) | NOS3NOS1NOS2HTR2CHTR2B | |
| SCHEMBL1166433 | 0.76 | HTR2A (0.52) | USP2HTR2CUSP30HTR2A | |
| SCHEMBL4695930 | 0.76 | HTR2A (0.64) | HTR2CHTR2A | |
| SCHEMBL30962765 | 0.75 | HTR2C (0.49) | NOS3NOS1NOS2HTR2CHTR2B | |
| SCHEMBL30962640 | 0.75 | HTR2C (0.49) | NOS3NOS1NOS2HTR2CHTR2B | |
| SCHEMBL31203041 | 0.75 | HTR2C (0.49) | NOS3NOS1NOS2HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10781180-B2 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20190263757-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20160304463-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-8785441-B2 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130237540-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2013-09-12 | — | — | US | disclosed |
| EP-1978019-A1 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | Arena Pharmaceuticals, Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1833799-B1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT-2a SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070244086-A1 | 3-Phenyl-Pyrazole Derivatives as Modulators of the 5-Ht2A Serotonin Receptor Useful for the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070207994-A1 | 3-Phenyl-pyrazole derivatives as modulators of the 5-HT2a serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237540-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR3A, HTR3B | NOS3 85/4885NOS1 250/4885NOS2 162/4885 |
| US-20160304463-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR3A, HTR2A | NOS3 109/4885NOS1 278/4885NOS2 179/4885 |
| US-20070207994-A1 | 3-Phenyl-pyrazole derivatives as modulators of the 5-HT2a serotonin receptor useful for the treatment of disorders related thereto | HTR5A, HTR3A, HTR3B | NOS3 85/4885NOS1 250/4885NOS2 162/4885 |
| US-20190263757-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR3A, HTR2A | NOS3 109/4885NOS1 278/4885NOS2 179/4885 |
| US-10781180-B2 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | HTR5A, HTR3A, HTR2A | NOS3 109/4885NOS1 278/4885NOS2 179/4885 |
| US-20070244086-A1 | 3-Phenyl-Pyrazole Derivatives as Modulators of the 5-Ht2A Serotonin Receptor Useful for the Treatment of Disorders Related Thereto | HTR5A, HTR3A, HTR2A | NOS3 109/4885NOS1 278/4885NOS2 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.